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Headache is one of the most common disorders of the nervous system. Headache is further classified into 
migraine, tension-type headache, and cluster headache. Migraine occurs in about 12% of people age 12 and 
older in the United States (17% of women and 6% of men). It is about three times more common in women 
than men. It is estimated that every 10 seconds someone in the United States goes to the emergency room 
with a migraine or headache due to the excruciating pain, severe nausea or dehydration, drug interactions, or 
side effects from headache medications. In recent years there has been a growing interest and demand from 
the public for ‘natural’ treatments such as vitamins and supplements in trying to control migraine headaches. A 
variety of natural supplements, vitamins and herbal preparations have been promoted as having efficacy in 
migraine prophylaxis. This mini-review analyzes the various natural and herbal therapies for the prophylaxis and 
treatment of migraine. 
 




The new millennium has ushered in an era of 
science that will revolutionize a great majority of our 
day-to-day activities and life style. Driven by 
chemistry, but increasingly guided by pharmacology 
and clinical sciences, drug research has contributed to 
the progress of medicine during recent times.  An 
unprecedented advance in biological knowledge and 
vast improvement in methodologies are generating a 
cornucopia of drug targets creating big opportunities 
for the design of small molecules with great 
therapeutic potential. 
The advent of molecular biology and genetic 
science is having a deep impact on drug discovery. 
Molecular pharmacology has revolutionized the 
process of drug discovery by enabling the precise 
control of the expression of drug targets such as 
receptors and enzymes. 
Nature has been a source of medicinal agents 
for long time and an impressive number of modern 
drugs have emerged from natural sources, many based 
on their use in traditional medicine. 
Determination of structure and nature of 
proteins associated with disease process is of vital 
importance for drug development. With the 
development of new molecular targets based on these 
proteins there is an increasing demand for novel 
diversified molecules for pharmacological evaluations. 
Natural products will play a crucial role in meeting 
such demands through sustained investigations. 
Medicinal plants play a key role in the human 
health care. Majority of the world population relies on 
the use of traditional medicine, which is 
predominantly based on plant material. These medical 
practices originated from times immemorial and 
developed gradually, to a large extent, by relying or 
being based on practical experiences without 
significant references to modern scientific principles.1 
The use of herbal medicines is steadily growing in the 
western world, with approximately 40% of the 
population reporting the use of herbs to treat medical 
illnesses within the past year. Public, academic and 
government interests in traditional medicines is 
growing exponentially due to the increased incidence 
of the adverse drug reactions and economic burden of 
the modern system of medicine.2 The major hindrance 
in the amalgamation of herbal medicines into modern 
medicinal practices is the lack of scientific and clinical 
data, and better understanding of efficacy and safety of 
the herbal products. The traditional use can provide 
valuable clues for the selection, preparation and 
indications for use of herbal formulation, as efficacy 
has been established by the common use. The 
historical background provides the source of 
information to study the specific plant species to be 
used for a particular disease with great potential. 
Hence, a systematic approach, through experimental 
and clinical validation of efficacy, is required for a 
traditional medicinal plant, similar to the validation 
process utilized in modern medicine.2 
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Although herbal medicines are effective in the 
treatment of various ailments, very often these drugs 
are unscientifically exploited and/or improperly used 
and a detailed pharmacological evaluation of these 
plants and their taxonomical relatives can lead to the 
development of invaluable herbal drugs for many 
dreaded diseases. 
Ethnopharmacology has come to stay as 
interdisciplinary scientific exploration of biologically 
active agents, with traditionally observed benefits in 
man.2 Ethnomedical leads and subsequent 
ethnopharmacological studies discovered many plant-
derived drugs used in modern medicine. There are 
more than 100 drugs of known structure that are 
extracted from higher plants and used in allopathic 
medicine. Botanicals serve humans as source of 
valuable chemicals. In today’s US $ 300 billion global 
pharmaceutical market, approximately 25% of all 
prescriptions contain active agents originally derived 
from plants.2  
Phytomedicines have three distinct advantages 
1) botanical extracts can be directly evaluated without 
initial chemical isolation for clinical efficacy, 2) 
increased solubility/bioavailability in crude forms, and 
3) synergy between different active constituents. 
 
Migraine: clinical manifestations and 
therapies 
Migraine is characterized by attacks of intense 
pulsatile and throbbing headache, typically unilateral in 
nature with or without aura. Attacks are episodic and, 
by their very nature resolve with time. Associated 
symptoms, such as nausea, vomiting and heightened 
sensitivity to light (photophobia), and sound 
(phonophobia) may occur during the headache phase.  
The headache phase may be preceded by 
symptoms, such as mood fluctuations and 
gastrointestinal disturbances. A minority of patients 
experience a more specific sensory disturbance prior 
to the headache, called 'aura' which usually has visual 
disturbances. Migraine affects a substantial fraction 
(10-20 %) of world population (more women than 
men).3 
With regard to the pathophysiology of 
migraine, several theories have been proposed; the 
major three, proposed till date, are vasodilatory (due to 
cerebral vasodilatation), neurological (abnormal 
neurological firing) and neurogenic dural inflammation 
mechanism (release of inflammatory neuropeptides). 
The objective of today’s acute migraine therapy is to 
reverse the vasodilatation in the intracranial, 
extracerebral vessels and thereby abolish pain.3  
The drugs used for the treatment of migraine 
can be divided into two groups: agents that abolish the 
acute migraine headache and agents aimed at its 
prevention. In the last decade there has been a 
tremendous progress in the acute migraine therapy, 
with sumatriptan, belonging to a new class of drugs, 
known as 5-HT1B/1D receptor agonists, providing the 
best relief in migraine.3 The success of sumatriptan, 
which is a gold standard in migraine therapy, stirred up 
a research interest in the field of migraine.  These 
agents have changed the lives of countless patients 
with migraine. Currently prophylactic treatments for 
migraine include calcium channel blockers, 5-HT2 
receptor antagonists, beta adrenoceptor blockers and 
-amino butyric acid (GABA) agonists, etc.4 
Unfortunately, many of these treatments are 
nonspecific and not always effective. Perhaps due to 
the involvement of multiple receptors, the ergot 
alkaloids are associated with a number of side effects 
including nausea and vomiting, gangrene and 
myocardial infarction. The disadvantages of the 
triptans are their high cost and the restrictions on their 
use in the presence of cardiovascular diseases and 
other side effects including feelings of tingling, heat, 
pain, heaviness or tightness in any part of the body, as 
well as flushing, dizziness, weakness, drowsiness and 
tiredness.5 Thus, there exists an imperative need 
towards an effective antimigraine therapy, which has 
fewer side effects. 
Phytomedicine has offered an alternative 
source of therapy for migraine sufferers, and provided 
some additional information about the pathogenesis of 
migraine. Feverfew (Tanacetam parthenium) and 
butterbur (Petasites hybridus) are some of the plants 
that have been used for centuries for migraine relief.6 
 
The nutraceutical approach for the treatment 
of migraine  
The exploitation of plants for medicines has a 
long and honorable history. It was also linked with the 
initial development of the science of pharmacology, 
which used natural products to elucidate physiological 
process. The pharmacological evaluation of natural 
products therefore forms an intrinsic part of 
pharmacognosy, one of the original disciplines of the 
pharmaceutical profession. 
Natural products are the basis of many 
standard drugs used in modern medicine, namely 
digoxin, hyoscine, theophylline, ergometrine, 
pilocarpine, vincristine and vinblastine. Plant 
compounds have also served as templates for the 
development of many drugs, including local 
anesthetics such as lignocaine from cocaine; analgesics 
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and cough suppressants developed from opiates etc. 
Some of the important developments are taxol from 
Pacific Yew, Taxus brevifolia and artemisinin from 
Artemisia annua. Garlic, an ancient remedy, is one now 
showing its true potential as an antisclerotic and 
antithrombotic. Plant drugs also serve efficient 
treatments for some conditions where ‘conventional’ 
medicine has little to offer, such as liver damage, 
where lignans from Silibum marianum can prevent 
fatalities by death cap mushroom (Amanita phalloides) 
poisoning and infectious hepatitis. During the last few 
decades, there has been a resurgence of interest in 
plants as sources of medicines and of novel molecules 
for use in the elucidation of physiological/biochemical 
phenomena. There is a worldwide ‘green’ revolution, 
which is reflected in the belief that herbal remedies are 
safer and less damaging to the human body than 
synthetic drugs. Laboratories around the world are 
engaged in the screening of the plants for biological 
activity with therapeutic potential. One major criterion 
for the selection of a plant for such study is traditional 
healers’ claim for its therapeutic usefulness.7 
The clinical applications of taxol, etoposide 
and artemisinin have boosted the interest in higher 
plants as sources of new drugs. Despite the belief that 
majority of clinical drugs are synthetic in origin, it is 
interesting to note that 6 out of 20 pharmaceutical 
prescription drugs dispensed in last decade were 
natural products and over 50% of top 20 drugs could 
be linked to natural product research. There still 
remains an urgent need to develop new clinical drugs 
and this can be exemplified by the numerous diseases 
which result from the malfunction of the central 
nervous system e.g. Alzheimers and Parkinson’s 
disease, epilepsy, migraine, pain, schizophrenia and 
sleeping disorders as well as other life threatening 
challenges like AIDS and various types of cancer.7 
  
Feverfew (Tanacetum parthenium)  
Leaves or infusions of feverfew, a short bushy 
perennial herb widely distributed in UK, have long 
been used as a folk remedy for fever, arthritis and 
migraine. One of the active ingredients, parthenolide 
in feverfew is the sesquiterpene lactone that has 
shown inhibitory effects on serotonin release and 
platelet aggregation in vitro.8 Also feverfew reportedly 
inhibits the synthesis of 5-lipoxygenase, leukotrienes, 
prostaglandins and thromboxanes that mediate 
inflammation. Clinical trials appear to indicate that 
feverfew taken prophylactically has beneficial effects 
in patients who suffer from migraine.8 
There were four trials conducted to evaluate 
the efficacy of feverfew in patients with migraine. One 
of the four trials conducted with feverfew in a self-
selected group of feverfew users showed that 
withdrawing feverfew led to a statistically significant 
increase in headache frequency.9 A pilot study of 17 
patients with migraines were given capsules of freeze 
dried feverfew leaves or placebo daily. Those who 
received placebo had a tripling in the frequency of 
migraine attacks. The placebo group had a tripling in 
the frequency of migraine attacks. Patients on placebo 
reported increased nervousness, tension headaches, 
insomnia, or joint stiffness, constituting a post 
feverfew syndrome. The other conventional trial was 
conducted in a larger group of patients with migraine, 
most of whom (71%) had never used feverfew.10 This 
trial reported a smaller difference between feverfew 
and the control treatment, but still found the 
difference to be statistically significant, in favor of 
feverfew. The third trial was a double blind, 
randomized crossover study that tested the efficacy of 
feverfew compared with placebo, concluding that the 
treatment with feverfew was associated with a 
significant reduction in pain intensity and associated 
symptoms (nausea, vomiting, photophobia and 
phonophobia).11 The fourth study found an 
insignificant difference between feverfew given as an 
alcoholic extract and placebo for reducing migraine 
frequency.12 
A double-blind study which evaluated the 
dose response of stable feverfew extract (MIG-99) at 
three dose levels (2.08, 6.25 and 18.75 mg three times 
a day). The results indicated that the frequency of the 
attacks is reduced in a dose dependent manner. 
However, the extract failed to exhibit any migraine 
prophylactic effect.12 
The same formulation has been reevaluated at 
the dose of 6.25 mg three times in a placebo 
controlled parallel-group study. The results showed a 
statistically significant and clinically relevant difference 
between MIG-99 and placebo regarding the reduction 
of migraine frequency. The intention-to-treat analysis 
yielded a decrease in migraine attacks by 1.9 attacks 
per month by MIG-99 when baseline covariables are 
taken into account. It has been suggested that MIG-99 
represented an effective prophylactic migraine 
therapy.13 
Limited information indicates that adverse 
events were no more common with feverfew than the 
same with placebo. Feverfew’s side effects included 
mouth ulceration and a more widespread oral 
inflammation associated with loss of taste. Feverfew’s 
mechanism of action is uncertain. It is rich in 
sesquiterpene lactones, especially parthenolide, which 
may be a non-specific norepinephrine, serotonin, 
bradykinin, prostaglandin and acetylcholine antagonist. 
The biological variation in the sesquiterpene lactone 
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content and the long-term safety and effectiveness of 
feverfew are of concern.13 
Feverfew is available in capsule, tablet and 
liquid extract forms. All the feverfew preparations are 
standardized to contain 0.2% of parthenolide. 
Feverfew should not be used by pregnant women, as it 
may cause uterine contraction resulting in miscarriage 
or preterm labor. It can also cause allergic reactions; 
patient with allergies to other members of the daisy 
family, including ragweed and chrysanthemums, are 
more likely to be allergic to feverfew.13 
 
Butterbur (Petasites hybridus) 
Butterbur is a perennial shrub found 
throughout Europe as well as parts of Asia and North 
America. It has been traditionally used for treating 
cough, asthma and skin wounds. Currently the primary 
therapeutic uses of butterbur are prophylactic 
treatment of migraine and as an antispasmodic agent. 
The extract of the rhizomes of Petasites hybridus and its 
constituents, petasine and isopetasine are shown to 
exhibit strong vasodilatory activity on smooth muscle 
preparations, comparable to papaverine.14 Moreover, 
the components of Butterbur are found to possess 
anti-inflammatory activity through the inhibition of 
leukotriene synthesis. Recent in vitro study, the extract 
of butterbur exhibited direct- and lipopolysaccharide 
(LPS) induced - inhibition of cyclooxegenase-2 and 
thus the release of prostaglandin E2 (PGE2) in 
primary rat microglial cells. Furthermore, the extract 
prevented the LPS-induced activation of p42/44 
mitogen activated protein kinase activation in the same 
cell lines.15 Intravenous administration of iso-S-petasin 
produced dose-dependent hypotensive and 
bradycardiac responses in anesthetized rats. Iso-S-
petasin, also attenuated the Ca2+ induced contractions 
in depolarized rat aorta. Studies in cultured vascular 
smooth muscle cells revealed that iso-S-petasin 
possesses L-type voltage dependent calcium channel 
antagonistic activity. These findings serve as the 
pharmacological basis for the prophylactic treatment 
of migraine with butterbur.  
In a double-blind placebo controlled clinical 
study Petasites hybridus extract (Petadolex) or placebo 
was administered at a dosage of 2 capsules (25 mg 
each) twice a day for 12 weeks. The results of the 
study demonstrated that Petadolex is effective in the 
prophylactic treatment of migraine. The extract 
reduced the frequency of attacks by a maximum of 
60% as compared to baseline.16 More recently, a 
number of studies with various doses of Petasites 
extract have been reported. In a three arm parallel 
group study 75 mg and 50 mg doses (twice a day) of 
the extract are studied with placebo for 4 months. The 
75 mg and 50 mg doses reduced the attack frequency 
by 48 % and 36 % while only 26 % observed in the 
placebo group. In yet another multi-center open label 
study Petasite extract was studied in children and 
adolescents at doses of 50 and 150 mg per day for 4 
months. The extract showed reduction in attack 
frequencies and the treatment was well tolerated in 
children and teenagers. Safety data from clinical trials, 
postmarketing surveillance and pharmacovigilence 
suggest butterbur extract is safe in the treatment in 
human.16  
As Petadolex is shown to be safe and 
tolerable, it might pose as a good option in the 
treatment of pediatric migraine. In a multicenter 
prospective open-label study involving children and 
adolescents with migraine, Petadolex showed 
reduction in 50% of all patients and 91% participants 
felt substantially or at least slightly improved after 4 
months of treatment.17  
 
Sapindus trifoliatus and other herbal remedies 
Sapindus trifoliatus is a medium sized deciduous 
tree found in south India. High content of saponins 
and sugars have been reported in the pericarp. In the 
folklore literature, fruits are reported to possess 
emetic, tonic, astringent and anthelmintic properties 
and are used in the treatment of asthma, colic due to 
indigestion, diarrhoea, cholera, tubercular glands, 
paralysis of the limbs and lumbago. A thick watery 
solution of the pulpy mesocarp is introduced into the 
nose of the patient for relief in hemicrania and for 
restoring consciousness during epileptic and hysteric 
fits. Further, fruits of Sapindus trifoliatus have been 
scientifically investigated for their anti-pruritic, anti-
spermatogenic, anti-androgenic and spermicidal 
properties. 
Recently, Sapindus trifoliatus has been 
investigated in various in vitro and in vivo models of 
nociception, migraine and inflammation The aqueous 
extract of Sapindus trifoliatus (ST), exhibited affinity 
towards, 5-HT2B receptors in an isolated rat fundus 
assay. However, ST did not exhibit affinities towards 
acute migraine targets (viz. 5-HT1B/1D receptors and α-
adrenoceptors) in experiments conducted in various in 
vitro tissues.18 At moderately high concentrations, ST 
inhibited the serotonin release from human platelets. 
ST exhibited anti-nociceptive activity in various central 
and peripheral pain models. ST exhibited analgesic 
activity in hyperalgesic pain models predictive of in vivo 
migraine models. Data obtained from in vitro and in vivo 
studies on various inflammatory models suggest that 
ST has anti-edematogenic activity in acute models of 
inflammation. Studies on behavioral and neurological 
animal models revealed the dopaminergic and 
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serotonergic modulatory role of ST. However, so far 
no human trials have been reported with the use of 
Sapindus trifoliatus.19-21 
A wealth of literature lends to support the use 
of several herbal medicines in the treatment of 
migraine and other types of headache. Cannabis 
(Cannabis sativa), Ginger (Zingiber officinale) and Sweet 
bay (Laurus noblilis) are not to be excluded from the 
list. More specifically, there is a recent upsurge in the 
use of cannabis in the treatment of migraine. 
Anandamide, the endogenous ligand of cannabinoid 
CB1 and CB2 receptors, was able to inhibit neurogenic 
dural vasodilatation, calcitonin gene-related peptide-, 
capsaicin-, and nitric oxide-induced dural vessel 
dilation in the rat intravital microscopy model of 
trigemnovascular activation. The CB1 receptor 
antagonist AM251 was able to reverse the above 
anandamide mediated inhibition. It was speculated 
that anandamide may tonically inhibit neuronal firing 
in the trigeminovascular system.22 
 
Riboflavin 
Riboflavin, the water-soluble vitamin, 
improves energy metabolism in the body. It plays a 
vital role in membrane stability and the maintenance 
of energy-related cellular functions. It can be found in 
certain foods such as milk, meat, eggs, nuts, enriched 
flour, and green vegetables. It has been proposed that 
the brain cells of some people with migraine may have 
a mitochondrial dysfunction resulting in impaired 
oxygen metabolism. It is further thought that taking a 
riboflavin supplement has the potential to increase the 
mitochondrial energy efficiency in an individual who 
has migraine. In short, riboflavin would be taken with 
the aim of improving the way oxygen is metabolized in 
the brain. In a well-designed randomized study 
riboflavin exhibited beneficial effects in migraine 
prophylaxis. In this study daily use of 400 mg of 
riboflavin for 3 months resulted in around 50% 
reduction in attacks in approximately 60% of the study 
population, which was significantly higher than 
placebo. In another pilot study, riboflavin augmented 
the effects of beta-blockers indicating combining these 
two treatments may increase the efficacy.24  
 
Magnesium 
Magnesium is one of the essential cation in 
the human body which plays a vital role in multiple 
physiological processes. An adult has about 25 grams 
of magnesium in their body (mostly in the bones). 
More than two thirds of our usual daily intake of 
magnesium comes from cereals and vegetables. 
Literature suggests the role of magnesium in various 
diseases including cortical spreading depression, 
platelet aggregation and vasoconstriction. Also the 
levels of magnesium reportedly influences other 
migraine related pathways including serotonin, nitric 
oxide synthesis and release and inflammatory 
mediators like substance P. It has been observed in a 
small study, 50% of migraine patients showed low 
levels of ionized magnesium, whom showed 
improvements with the administration of 1 g of 
intravenous magnesium. A prospective study showed 
decreased magnesium concentrations in women during 
menstrual migraine attacks. Interestingly, magnesium 
treatment has been shown to be effective in various 
randomized controlled trials. In one study,24 women 
with menstrual migraine received 360 mg of 
magnesium pyrrolidone carboxylic acid experienced 
reduction in the number of days with headache and 
total pain index and improvement in menstrual 
distress questionnaire score. In  two different studies, 
a 600 mg dose of trimagnesium dicitrate  or 
magnesium citrate taken daily significantly reduced the 
migraine frequency and severity (37/38).25                                                                      
 
Concluding remarks  
The unmet needs of antimigraine therapy still 
exist as migraine is a disorder with a variety of 
complex etiologies. It remains the hope of research 
scientists that in the not too distant future we shall see 
a new class of antimigraine drugs arising from the 
understanding molecular pathophysiology of migraine 
in the post-triptan era. Currently feverfew is the only 
herbal, which is extensively used in the prophylactic 
treatment of migraine. However, the proof-of-concept 
clinical studies are awaited with interest for the 
potential use of butterbur and Sapindus trifoliatus for the 
treatment of migraine. The data from the studies of 
Petasites hybridus and Sapindus trifoliatus support the 
ethno-medical application of these plants in the 
treatment of migraine (hemicrania) and provide new 
hope for the development of novel ethno-leads 
towards the pharmacotherapy of migraine. 
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